¡Ya estamos en !
Descubre más
GLS
Gelesis Holdings, Inc.
Excluida de cotización
GLS dejó de cotizar en bolsa el 10 de abril de 2023.
Acerca de: Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Empleados: 93
Noticias
Positivo
Neutral
Negativo
Sentimiento
3 meses
Positivo
0%
Neutral
0%
Negativo
0%
No hemos recibido artículos de noticias recientes sobre GLS.
Gráficos de precios implementados con Lightweight Charts™